Skip to main content
. Author manuscript; available in PMC: 2015 Aug 18.
Published in final edited form as: Angiogenesis. 2014 Feb 26;17(3):661–673. doi: 10.1007/s10456-014-9422-9

Fig. 1.

Fig. 1

Schematic representation of protocol used to derive topotecan/pazopanib resistant ovarian cancer variants 7SD and 7AS using the SKOV-3-13 cell line as a starting point. Mice were treated with metronomic topotecan plus pazopanib for 13 weeks. Six weeks after cessation of treatment, tumor growth began to recur. At this time, treatment was re-initiated but mice failed to respond to the therapy